An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

Trial Identifier: D5180R00039
Sponsor: AstraZeneca
Start Date: November 2024
Primary Completion Date: September 2026
Study Completion Date: September 2026
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, China Beijing, China, China
China, China Chengdu, China, China
China, China Foshan, China, China
China, China Fuzhou, China, China
China, China Guangzhou, China, China
China, China Hangzhou, China, China
China, China Hefei, China, China
China, China Jinan, China, China
China, China Kunming, China, China
China, China Naijing, China, China
China, China Nanchang, China, China
China, China Ningbo, China, China
China, China Qingdao, China, China
China, China Quanzhou, China, China
China, China Shanghai, China, China
China, China Shenyang, China, China
China, China Shenzhen, China, China
China, China Shijiazhuang, China, China
China, China Suining, China, China
China, China Taiyuan, China, China
China, China Tianjin, China, China
China, China Urumqi, China, China
China, China Wenzhou, China, China
China, China Wuhan, China, China
China, China Wuxi, China, China
China, China Xian, China, China
China, China Zhengzhou, China, China
China, China Zhuhai, China, China